Angiotech Announces Financial Results for the Second Quarter Ended June 30, 2012

VANCOUVER, Aug. 14, 2012 /CNW/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") announced that it released its financial results for the second quarter ended June 30, 2012.

Angiotech will host a conference call discussing its first quarter financial results on August 15, 2012 at 1:00 PM ET (10:00 AM PT). Details regarding the conference call can be found on Angiotech's website at www.angiotech.com.

"We are extremely pleased to announce our third consecutive quarter of significantly improved financial results. Our improved revenue growth, cash flows, liquidity and profitability are a culmination of the hard work and dedication of our team following the conclusion of our restructuring and business change initiatives last year," said Thomas Bailey, Angiotech's President and CEO.

"In addition, as a result of our improved business performance, we were recently able to complete an important transaction that extends the maturity date of much of our outstanding debt to December 2016. Our exchange offer transaction was strongly supported by our existing creditors and was substantially oversubscribed, and we look forward to using this transaction as a launch point for certain new strategic initiatives we are contemplating for 2013 and beyond," said Mr. Bailey.

Selected important recent developments, and certain highlights from the second quarter ended June 30, 2012, include:

• Refinancing of $225 million of Senior Floating Rate Notes. Angiotech recently concluded a transaction to exchange a portion of its outstanding Senior Floating Rate Notes due December 1, 2013 (the "Existing Notes") for new 9% Senior Notes due December 1, 2016 (the "New Notes"). This refinancing transaction significantly alleviates our near term refinancing risk, due to the three-year extension of the maturity date for the New Notes. In addition, by re-domiciling the New Notes in the U.S., the after-tax cash cost of the New Notes is expected to be substantially similar to the Existing Notes. On July 3, 2012, Angiotech launched an offer to exchange up to a maximum of $200 million in aggregate principal amount of the outstanding Existing Notes ("Maximum Principal Exchange Amount") for the New Notes issued by Angiotech Pharmaceuticals (US), Inc. pursuant to an Offering Memorandum and Consent Solicitation Statement (the "Exchange Offer"). On July 27, 2012, as a result of significant demand for New Notes by holders of our Existing Notes, we elected to amend the Exchange Offer to increase the Maximum Principal Exchange Amount to $225 million. On August •13, 2012, $225 million of the $255.5 million tendered Existing Notes were irrevocably extinguished and exchanged, on a pro rata basis, for approximately $230 million of New Notes. All Existing Notes that were tendered by the prescribed July 23, 2012 early tender date, which represented the substantial majority of Existing Notes tendered, received New Notes with a principal amount constituting a 2% premium (the "Early Tender Premium") to the principal amount of the Existing Notes so exchanged. We expect that the remaining $100 million of Existing Notes may be repaid with excess cash generated from operations or potential contingent consideration to be received from the Quill transaction discussed below, or refinanced at or prior to their maturity.
  
  
• Revenue. During the quarter ended June 30, 2012, our Medical Device Products segment generated higher revenue than any of the previous five quarters. During the three months ended June 30, 2012 our Medical Device Products recorded sales growth of 8% as compared to the same period in 2011. Overall, we expect to observe continued sales growth in our Medical Device Products throughout the remainder of 2012 as compared to 2011. Improved sales growth in our Medical Device Products segment is primarily the result of the following factors: (i) improved commercial and operational focus on our most significant and competitive product lines subsequent to the conclusion of our balance sheet and corporate restructuring efforts; (ii) continued growth of our proprietary Quill™ product line; and (iii) stabilization and growth of our medical device component manufacturing business, with growth observed in both existing and new medical device component customers.
  
  
• Adjusted EBITDA and Debt Reduction. For the three months ended June 30, 2012, we reported Adjusted EBITDA of $18.5 million, which represents a 79% increase over Adjusted EBITDA of $10.3 million reported during the same period in 2011. Adjusted EBITDA associated with our Medical Device Products segment was $14.5 million during the three months ended June 30, 2012, representing a 187% increase as compared to the same period in 2011. The remaining $4.0 million of Adjusted EBITDA recorded during the period was derived primarily from royalties received from our partners Boston Scientific Corporation and Cook Medical, Inc. relating to sales of TAXUS and Zilver PTX drug-eluting coronary stents, respectively. The significant improvement in our Adjusted EBITDA over the prior period was achieved through a combination of the growth in our Medical Device Products revenue as noted above, as well as savings that have been achieved from certain of our cost reduction and business restructuring initiatives that were substantively concluded in December of 2011.
  
  
• Operating Cash Flow and Liquidity. During the three months ended June 30, 2012, we reported positive cash flows from our operations of $23.4 million. This included $20.0 million received as a result of the transaction with Ethicon, Inc. (see below). This was the fourth consecutive quarter in which we have generated positive operating cash flows. This improvement in operating cash flows has positively impacted our total liquidity and capital resources. As at June 30, 2012, our cash and cash equivalents and short term investments totaled $58.6 million, and our available borrowing capacity under our revolving credit facility was $21.1 million, as compared to $25.4 million and $21.3 million as at December 31, 2011, respectively. We expect further significant improvements to our liquidity and capital resources in upcoming quarters, due to the improved profitability of our business as compared to prior periods, and as we continue to work with Ethicon to achieve the product development and launch milestones as described below.
  
  
• Net Debt Reduction and Credit Statistics.  As at June 30, 2012, we had no borrowings outstanding under our revolving credit facility. Our ratio of Net Debt to last 12 months Adjusted EBITDA decreased from 6.1 as at December 31, 2011 to 4.1 as at June 30 2012. Furthermore, based on annualizing our six months ended June 30, 2012 Adjusted EBITDA results, our ratio of Net Debt to Adjusted EBITDA would be 3.3.
  
  
• Business Strategy and Cost Realignment.  As previously announced, during the quarter ended December 31, 2011, we implemented various restructuring initiatives to better align our expense levels with our business model and capital structure; including headcount and other cost reductions in certain areas where our investment levels were high relative to our current sales or profitability, and the elimination of certain research and development programs. Through these changes, we achieved cost savings of $1.6 million (39% decrease) and $4.1 million (48% decrease) in our research and development expenses during the three and six months ended June 30, 2012, respectively, as compared to the same periods in 2011. Similarly, we achieved cost savings of $1.3 million (7% decrease) and $2.2 million (6% decrease) in our selling, general and administrative expenses during the three and six months ended June 30, 2012, respectively, as compared to the same periods in 2011. We expect to continue various initiatives to improve our business profitability and cost structure in future periods. Most significantly, in May 2012 we announced plans to conclude manufacturing activities at our facility in Denmark, and to move operations to selected other, lower cost locations in the U.S. to ensure certain of our interventional oncology product lines can remain competitive. This cost reduction project is currently in process, and we expect to conclude such activities in early 2013, subsequent to which we expect to begin realizing significant reductions in production costs, in particular for our Skater™ drainage catheter product line, which is one of our largest single product lines.
  
  
• Transaction with Ethicon, Inc. for proprietary Quill technology. As previously announced on April 4, 2012, we and certain of our subsidiaries recently entered into agreements with Ethicon LLC and/or Ethicon, Inc. (collectively "Ethicon"), a unit of Johnson & Johnson, Inc., which concluded the sale of certain intellectual property to Ethicon related to our Quill technology. We also entered into a Manufacturing and Supply Agreement ("MSA"), pursuant to which we will exclusively manufacture knotless wound closure products that utilize the Quill technology for Ethicon for an undisclosed term. On April 4, 2012, we received an initial payment of $20 million from Ethicon related to the acquisition of this Quill related intellectual property. In addition, we may earn up to an additional $42 million in contingent cash consideration from Ethicon, which will be paid out in various installments subject to (i) our transfer of certain know-how to Ethicon and (ii) the achievement of certain product development and launch milestones. In addition, a worldwide, royalty free license to all Quill intellectual property sold to Ethicon has been granted to us, thereby enabling us to continue to manufacture, market and sell Quill in any manner or market at our discretion.

Financial Information

This press release contains financial data derived from the unaudited consolidated financial statements for the three and six months ended June 30, 2012, the two months ended June 30, 2011 and the one and four months ended April 30, 2011. This press release should, therefore, be read in conjunction with our full unaudited interim consolidated financial statements and Management's Discussion and Analysis for three and six months ended June 30, 2012, which were filed on Form 10-Q on August 14, 2012 with the United States (U.S.) Securities and Exchange Commission ("SEC") and posted on the Investor section of our website at www.angiotech.com.

Amounts, unless specified otherwise, are expressed in U.S. dollars. Financial results are reported in accordance with U.S. GAAP unless otherwise noted.

Non-GAAP Financial Information

Certain financial measures in this press release are prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"). In addition, we have presented adjusted earnings before interest, taxes, depreciation and amortization ("Adjusted EBITDA"), which is a non-GAAP financial metric that excludes certain non-cash and non-recurring items. Management uses Adjusted EBITDA to establish operational goals, and believes that this metric may assist investors in evaluating the results of our business and analyzing the underlying trends over time. In addition, our creditors may monitor this metric to measure compliance with certain financial covenants in our lending agreements, or assess the operating and cash flow performance of our business. Investors should consider our non-GAAP Adjusted EBITDA in addition to, and not as a substitute for, or as superior to, financial metrics prepared in accordance with GAAP. A reconciliation of our non-GAAP Adjusted EBITDA to our GAAP-based net income or loss has been included in the appendix to this press release. We have also included explanations about our use of Adjusted EBITDA and a detailed description of the adjustments made.

Fresh Start Accounting

On May 12, 2011 we implemented a recapitalization transaction which, among other things, eliminated our $250 million 7.75% Senior Subordinated Notes due in 2014 and $16 million of related interest obligations in exchange for new common shares in Angiotech (the "Recapitalization Transaction"). In connection with this Recapitalization Transaction, we were required to adopt fresh start accounting in accordance with ASC No. 852—Reorganization on April 30, 2011 (the "Convenience Date"). The adoption of fresh start accounting resulted in a new entity for financial reporting purposes. Angiotech is therefore referred to as the "Predecessor Company" for all periods preceding the Convenience Date and the "Successor Company" for all periods subsequent to the Convenience Date. However, we believe that the comparison of results from the three and six months ended June 30, 2012 and 2011 still provides the best comparison and analysis of our operating results.

Upon implementation of fresh start accounting, the estimated reorganization value was allocated to our assets based on their estimated fair values; the deficit, additional paid-in-capital and other comprehensive income balances were eliminated; and debt and equity balances were revalued at their estimated fair values. Our estimated reorganization value was determined in collaboration with an independent financial advisor specifically for the purposes of fresh start accounting. As our estimated reorganization value is inherently subject to significant uncertainties, there is no assurance that the estimates and assumptions used in these valuations will be realized and actual results may differ materially. After the estimated reorganization value was assigned to tangible assets and identifiable intangible assets, the excess of the estimated reorganization value over and above the identifiable net asset values was recorded as goodwill.

For further discussion of fresh start accounting and its impact on historical operating results, please refer to our audited consolidated financial statements and Management, Discussion and Analysis for the eight months ended December 31, 2011 filed on Form 10-K with the SEC on March 29, 2012.

ANGIOTECH PHARMACEUTICALS INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(All amounts expressed in thousands of U.S. dollars, except share and per share data)
(Unaudited)

		Successor Company							Predecessor Company			Combined
		Three months ended			Two months ended				One month ended			Three months ended
		June 30,			June 30,				April 30,			June 30,
		2012			2011				2011			2011
REVENUE
Product sales, net		$	56,523		$	35,902			$	16,365		$	52,267
Royalty revenue		4,804			1,068				5,285			6,353
License fees		11			—				24			24
		61,338			36,970				21,674			58,644
EXPENSES
Cost of products sold		27,322			26,934				8,291			35,225
License and royalty fees		63			50				—			50
Research and development		2,423			2,829				1,156			3,985
Selling, general and administration		17,784			12,781				6,191			18,972
Depreciation and amortization		8,428			5,690				3,088			8,778
Write-down of assets held for sale		—			—				570			570
Write-down of property, plant and equipment		692			—				—			—
		56,712			48,284				19,296			67,580
Operating income (loss)		4,626			(11,314)				2,378			(8,936)
Other income (expenses)
Foreign exchange (loss) gain		214			492				(366)			126
Other income		240			112				10			122
Interest expense		(4,306)			(3,032)				(2,217)			(5,249)
Impairments and realized losses on investments		(68)			—				—
Total other expenses		(3,920)			(2,428)				(2,573)			(5,001)
Income (loss) before reorganization items and income taxes		706			(13,742)				(195)			(13,937)
Reorganization items		—			—				329,826			329,826
Gain on extinguishment of debt and settlement of other liabilities		—			—				67,307			67,307
Income (loss) before income taxes		706			(13,742)				396,938			383,196
Income tax expense (recovery)		3,654			506				(581)			(75)
Net (loss) income		(2,948)			(14,248)				397,519			383,271
Basic and diluted net (loss) income per common share		$	(0.23)	(1)	$	(1.12)	(1)		$	4.67	(2)
Basic and diluted weighted average number of common shares outstanding (in thousands)		12,826			12,721				85,185

(1)	There is no dilutive effect on basic weighted average common shares outstanding for the three months ended June 30, 2012 and the two months ended June 30, 2011, as Angiotech was in a net loss position during both periods.
(2)	There was no dilutive effect on the basic weighted average common shares outstanding for the one and four months ended April 30, 2011 given that the impact of stock options was anti-dilutive.

ANGIOTECH PHARMACEUTICALS INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(All amounts expressed in thousands of U.S. dollars, except share and per share data)
(Unaudited)

		Successor Company							Predecessor Company			Combined
		Six months ended			Two months ended				Four months ended			Six months ended
		June 30,			June 30,				April 30,			June 30,
		2012			2011				2011			2011
REVENUE
Product sales, net		$	111,147		$	35,902			$	69,198		$	105,100
Royalty revenue		10,722			1,068				10,941			12,009
License fees		20			—				127			127
		121,889			36,970				80,266			117,236
EXPENSES
Cost of products sold		52,006			26,934				32,219			59,153
License and royalty fees		174			50				68			118
Research and development		4,408			2,829				5,686			8,515
Selling, general and administration		35,431			12,781				24,846			37,627
Depreciation and amortization		17,451			5,690				14,329			20,019
Write-down of assets held for sale		—			—				570			570
Write-down of property, plant and equipment		865			—				215			215
		110,335			48,284				77,933			126,217
Operating income (loss)		11,554			(11,314)				2,333			(8,981)
Other income (expenses)
Foreign exchange (loss) gain		(56)			492				(646)			(154)
Other income		902			112				34			146
Interest expense		(8,558)			(3,032)				(10,327)			(13,359)
Impairments and realized losses on investments		(349)			—				—			—
Total other expenses		(8,061)			(2,428)				(10,939)			(13,367)
Income (loss) before reorganization items and income taxes		3,493			(13,742)				(8,606)			(22,348)
Reorganization items		—			—				321,084			321,084
Gain on extinguishment of debt and settlement of other liabilities		—			—				67,307			67,307
Income (loss) before income taxes		3,493			(13,742)				379,785			366,043
Income tax expense (recovery)		6,440			506				267			773
Net (loss) income		(2,947)			(14,248)				379,518			365,270
Basic and diluted net (loss) income per common share		$	(0.23)	(1)	$	(1.12)	(1)		$	4.46	(2)
Basic and diluted weighted average number of common shares outstanding (in thousands)		12,818			12,721				85,185

(1)	There is no dilutive effect on basic weighted average common shares outstanding for the three months ended June 30, 2012 and the two months ended June 30, 2011, as Angiotech was in a net loss position during both periods.
(2)	There was no dilutive effect on the basic weighted average common shares outstanding for the one and four months ended April 30, 2011 given that the impact of stock options was anti-dilutive.

ANGIOTECH PHARMACEUTICALS INC.
CONSOLIDATED BALANCE SHEETS
(All amounts expressed in thousands of U.S. dollars, except share data)
(Unaudited)

			Successor Company
			June 30,			December 31,
			2012			2011
ASSETS
Current assets
Cash and cash equivalents			$	57,991		$	22,173
Short-term investments			644			3,259
Accounts receivable			30,419			28,238
Income tax receivable			524			1,462
Inventories			38,179			34,304
Deferred income taxes, current portion			6,026			3,995
Deferred financing costs, current portion			434			—
Prepaid expenses and other current assets			2,973			3,167
Total current assets			137,190			96,598
Property, plant and equipment			35,427			39,189
Intangible assets			326,981			343,066
Goodwill			123,242			123,228
Deferred income taxes, non-current portion			2,566			2,165
Deferred financing costs, non-current portion			300			—
Other assets			310			3,860
Total assets			626,016			608,106
LIABILITIES AND SHAREHOLDERS' DEFICIT
Current liabilities
Accounts payable and accrued liabilities			25,658			30,537
Deferred income taxes, current portion			—			—
Income taxes payable			5,658			2,023
Interest payable			1,406			1,450
Deferred revenue, current portion			6,205			496
Revolving credit facility			—			40
Total current liabilities			38,927			34,546
Deferred revenue, non-current portion			18,069			3,771
Deferred income taxes, non-current portion			94,286			92,634
Other tax liabilities			6,118			5,729
Debt			325,000			325,000
Other liabilities			—			19
Total non-current liabilities			443,473			427,153
Shareholders' equity
Sucessor share capital			203,360			203,719
	Authorized:
	Unlimited number of common shares, without par value
	Common shares issued and outstanding:
	December 31, 2011 - 12,556,673
	June 30, 2012 - 12,526,702
Additional paid-in capital			9,349			8,552
Accumulated deficit			(63,393)			(60,446)
Accumulated other comprehensive income			(5,700)			(5,418)
Total shareholders' equity			143,616			146,407
Total liabilities and shareholders' equity			$	626,016		$	608,106

Forward Looking Statements

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities in 2012 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development, to expand manufacturing and commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to service our debt obligations; and any other factors referenced in our other filings with the SEC. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our quarter report for the three and six months ended June 30, 2012 filed with the SEC on August 30, 2012 on Form 10Q.

Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

^©2012 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

About Angiotech

Angiotech develops, manufactures and markets medical device products and technologies, primarily within the areas of interventional oncology, wound closure and ophthalmology. Our strategy is to utilize our precision manufacturing capabilities and our highly targeted sales and marketing capabilities to offer novel or differentiated medical device products to patients, physicians and other medical device manufacturers or distributors. For additional information about Angiotech, please visit our website at www.angiotech.com.

Appendix A: Presentation of Non-GAAP Financial Information

The financial results presented in this press release include Adjusted EBITDA, which is a non-GAAP financial measure.

Economic Substance of Non-GAAP Financial Measures

Our non-GAAP Adjusted EBITDA excludes certain non-cash, non-recurring and non-operating items, which may be unpredictable, volatile and not directly correlated to our operating performance. We believe exclusion of these items from our GAAP-based net loss may provide the following advantages: (i) improved understanding of trends underlying our business and performance; (ii) improved consistency across periods when measuring and assessing our operating performance; (iii) improved understanding of the cash flow and cash earnings generated by our business in a given period and as compared to prior periods; and (iv) improved comparability of our operating results to those of similar companies in our industry.

Examples of these non-cash, non-recurring and non-operating items may include: integration and restructuring expenses, reorganization adjustments, retrospective adjustments driven by accounting policy changes, financing charges, asset write-downs, impairment charges, foreign exchange fluctuations, stock-based compensation expense, acquisition related amortization charges and certain extraordinary litigation expenses. A detailed discussion of the excluded items is provided below (see "Description of Adjustments").

Investors are cautioned that Adjusted EBITDA does not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other issuers. Our non-GAAP Adjusted EBITDA is a supplemental metric and should not be viewed as a substitute for, or superior to, financial results and measures prepared in accordance with GAAP. We have prepared a reconciliation of our non-GAAP Adjusted EBITDA to our GAAP-based net income (loss) included in this Appendix. Management compensates for certain material limitations that may be applicable to our use of Adjusted EBITDA by reviewing our operating results that have been prepared in accordance with GAAP.

Use of Non-GAAP Financial Measures

Management uses Adjusted EBITDA when setting corporate and operational goals, and evaluating operating performance in connection with:

• Presenting, comparing and assessing the financial results and forecasts reported to our Board of Directors.
  
  
• Evaluating, managing and benchmarking our operating performance.
  
  
• Analyzing underlying trends in our business.
  
  
• Evaluating market position and performance relative to our competitors, many of which use the same or similar performance metrics.
  
  
• Establishing internal operating budgets and goals.
  
  
• Determining compensation under bonus or other incentive programs.
  
  
• Enhancing comparability from period to period.
  
  
• Assessing compliance with credit facility covenants.
  
  
• Providing vital information in assessing cash flows to service our significant debt obligations.
  
  
• Comparing performance with internal forecasts and targeted business models.
  
  
• Evaluating and valuing potential acquisition candidates.

The adjustments used to compute our non-GAAP Adjusted EBITDA are consistent with those excluded from operating results that may be used by our chief operating decision maker to make operating decisions and assess performance. We have provided this information to enable investors to analyze our operating results in the same way that management may use this information to assess our business relative to other periods, our business objectives and similar companies in our industry.

ANGIOTECH PHARMACEUTICALS, INC.
CALCULATION OF ADJUSTED EBITDA
(Unaudited)

		Three Months Ended						Six Months Ended
		June 30,						June 30,
(in thousands U.S.$)		2012			2011			2012			2011
GAAP net income (loss)		(2,948)			$	383,271		(2,947)			$	365,270
Interest expense on long-term debt		4,306			5,249			8,558			13,359
Income tax expense		3,654			(75)			6,440			773
Depreciation and Amortization		9,536			9,667			19,505			21,934
EBITDA		14,548			398,112			31,556			401,336
Adjustments:
Non-recurring revenue, net of license fees (a)		(11)			(24)			(20)			(127)
BSC royalty revenue accrual (a)		—			(1,333)			—			(1,333)
Non-recurring restructuring related charges (b)		2,017			488			3,432			43
Reorganization items and non-recurring transaction fees (c)		932			(329,826)			1,632			(321,084)
Stock-based compensation (d)		746			70			1,318			364
Litigation expenses (e)		—			19			—			164
Non-recurring production charge (f)		—			9,808			—			9,808
Foreign exchange loss (gain) (g)		(214)			(126)			56			154
Non-recurring gains and other income (i)		(240)			(122)			(902)			(146)
Impairment charges and realized losses on investments and other long-lived assets (h)		760			570			1,214			785
Gain on extinguishment of debt (i)		—			(67,307)			—			(67,307)
Adjusted EBITDA		$	18,538		$	10,329		$	38,286		$	22,657

	For an explanation of the adjustments used to derive our Adjusted EBITDA, please refer to the corresponding discussion in the "Description of Adjustments" section below.

Description of Adjustments

The following provides an explanation of each of the items that management has adjusted to derive its non-GAAP Adjusted EBITDA for the three and six months ended June 30, 2012.

(a) Non-Recurring Revenue and Other Revenue Adjustments

Our Adjusted EBITDA for the three and six months ended June 30, 2012 and 2011 exclude certain non-recurring and non-operating license revenue that is reported as part of our GAAP-based revenue.

We generally record royalty revenue from Boston Scientific ("BSC") on a cash basis due to the difficulty and unpredictability of estimating BSC's royalty before the reports and payments are received by the Company. This results in a lag of approximately one quarter between the times that the revenues are reported by BSC and subsequently received and recognized by us. For the purposes of implementing fresh start accounting on April 30, 2011, we were required to estimate the amount of BSC royalties that were earned during the month of April 2011 but expected to be received in August 2011. As a result, our GAAP net income for the three and six months ended June 30, 2011 includes a $1.3 million adjustment for this revenue accrual. We have added back this accrual-based revenue adjustment to our Adjusted EBITDA for the three and six months ended June 30, 2011.

(b) Non-Recurring Restructuring-Related Charges

Our Adjusted EBITDA excludes certain expenses or recoveries related to corporate reorganization or plant restructuring activities that we are pursuing.  These amounts, which are added back or deducted from our GAAP-based net income (loss) as appropriate, primarily represent severance costs; asset write-offs; contract renegotiation or termination fees; and other expenses associated with plant closures, transfers of production lines from one facility to another and plant headcount optimization initiatives that are not reasonably expected to recur in the future.

Our Adjusted EBITDA for the three months ended June 30, 2012 excludes the following restructuring charges: a $1.0 million fee paid to Biopsy Sciences, LLC to eliminate all future financial obligations owing under the original January 22, 2007 Asset Purchase and Assignment Agreement and Amended and Restated License Agreement, $0.5 million of charges related to the restructuring of our Vancouver head-office and $0.1 million of costs associated with restructuring initiatives at certain of our manufacturing facilities.

Our Adjusted EBITDA for the three months ended June 30, 2011 excludes the following restructuring charges: $0.4 million of costs associated with the movement of our Quill^TM Knotless Tissue Closure device production line from our Reading, Pennsylvania facility to our Puerto Rico facility, and $0.1 million of severance costs related to headcount reductions and residual reorganization costs from the 2008 closure of our Syracuse, New York manufacturing facility.

Our Adjusted EBITDA for the six months ended June 30, 2012 excludes the following restructuring charges: a $1.0 million fee paid to Biopsy Sciences, LLC to eliminate all future financial obligations owing under the original January 22, 2007 Asset Purchase and Assignment Agreement and Amended and Restated License Agreement, $1.1 million of non-recurring compensation and severance costs related to retention initiatives and headcount reductions in our research and development, sales and marketing and finance departments,  $0.9 million of charges related to the restructuring of our Vancouver head-office, and $0.1 million of costs associated with restructuring initiatives at certain of our manufacturing facilities.

Our Adjusted EBITDA for the six months ended June 30, 2011 excludes the following restructuring charges: $0.8 million of costs associated with the movement of our Quill^TM Knotless Tissue Closure device production line from our Reading, Pennsylvania facility to our Puerto Rico facility; $0.1 million of severance costs related to headcount reductions and residual reorganization costs from the 2008 closure of our Syracuse, New York manufacturing facility ; $0.2 million of restoration costs related to our decision to downsize our rentable space at one of our manufacturing facilities; $0.1 million of severance costs related to headcount reductions in our research and development department; a $0.4 million settlement fee related to the termination of property lease; a $1.0 million non-cash recovery on our rent expense resulting from an acceleration of the impact of certain leasehold inducements received in prior years, associated with our recent decision to downsize our rentable space at our Vancouver based head-office; and a $0.6 million recovery on a lease obligation that was previously recorded for a property lease that has since been terminated.

(c) Reorganization Items and Other Non-Recurring Transaction Fees

Our Adjusted EBITDA excludes certain extraordinary and non-recurring costs related to significant corporate transactions. These amounts are adjusted from our GAAP-based net (loss) income because they are highly variable and specific to the extent and nature of the transaction being undertaken. As these expenses are not directly correlated to our day-to-day operating performance and are due to transaction or related financing decisions made by us that are infrequent or volatile in nature and specific to the situation at that time, inclusion of these charges in our financial results makes it more difficult to compare our performance to that of prior periods or similar companies in our industry, or to assess the cash flow generation of our operations.

Our Adjusted EBITDA for the three months ended June 30, 2012 excludes: $0.9 million of non-recurring transaction fees and expenses that were incurred in connection with the completion of the transaction with Ethicon as described above.

Our Adjusted EBITDA for the three months ended June 30, 2011 excludes net reorganization gains, fees and expenses of $329.8 million related to our Recapitalization Transaction. The $329.8 million of net reorganization gains, fees and expenses consists of: (i) $341.2 million of non-cash gains realized due to fresh start accounting related adjustments; (ii) $9.0 million of professional fees paid to advisors for legal, accounting and other financial consulting services; (iii) a $0.8 million incentive fee payable under the terms of the Key Incentive Employment Plan ("KEIP") implemented as part of our Recapitalization Transaction, which is net of a $0.2 million tax recovery; (iv) a $1.4 million charge to stock based compensation expense related to the cancellation of the Predecessor Company's existing options and awards in accordance with the terms of the Recapitalization Transaction; and (v) $0.2 million cost adjustment for additional insurance costs required to indemnify existing directors and officers for a period of six years after the completion of the Recapitalization Transaction.

Our Adjusted EBITDA for the six months ended June 30, 2012 excludes $1.6 million of non-recurring transaction fees and expenses that were incurred in connection with the completion of the transaction with Ethicon as described above.

Our Adjusted EBITDA for the six months June 30, 2011 excludes net reorganization gains, fees and expenses of $321.1 million related to our Recapitalization Transaction. The $321.1 million of reorganization gains, fees and expenses consists of: (i) $341.2 million of non-cash gains realized due to fresh start accounting related adjustments; (ii) $17.9 million of professional fees paid to advisors for legal, accounting and other financial consulting services; (iii) $1.6 million of additional insurance costs required to indemnify existing directors and officers for a period of six years after the completion of the Recapitalization Transaction; (iv) a $0.8 million incentive fee payable under the terms of the KEIP, which is net of a $0.2 million tax recovery; (v) a $1.5 million recovery of prior year royalty fees that resulted from a Settlement and License Termination Agreement negotiated with our partner Rex Medical, LLP as part of the Recapitalization Transaction; and a $1.4 million charge to stock based compensation expense related to the cancellation of the Predecessor Company's existing options and awards in accordance with the terms of the Recapitalization Transaction.

(d) Stock-Based Compensation Expense

Our Adjusted EBITDA excludes amounts recorded for stock-based compensation expense. Stock-based compensation expense is added back to our GAAP-based net income (loss) because it is a non-cash charge required by GAAP, which represents an estimated additional cost associated with the issuance of restricted stock, restricted stock units and stock options to management and employees as part of their compensation. Such compensation expense is a non-cash expense calculated using the Black-Scholes or other similar methodology to derive the expected fair value of awards issued to employees under the Company's stock based compensation plans. Fair value calculations may be highly subjective, because they are dictated by the specific assumptions and inputs used in the model. Key assumptions and inputs may include our estimated stock price on the day the calculation is completed, the historical volatility of the Predecessor Company's stock price, historical volatilities of our industry peer groups, the estimated risk-free rate of return offered by the market and other factors, which are not directly correlated to our day-to-day operating performance and are difficult to determine, predict or forecast. In these respects and others (including the methodology that may be used to calculate such expense), methods and data that may be used to complete the calculation of stock-based compensation expense may vary widely from period to period or from company to company.

Inclusion of stock based compensation in our results makes it difficult to assess our operational cash flows as well as measure and compare our performance to that of similar companies in our industry, our operating goals or our performance in prior periods.

Our Adjusted EBITDA for the three and six months ended June 30, 2012 excludes stock-based compensation expense of $0.7 million and $1.3 million, respectively.

Our Adjusted EBITDA for the three and six months ended June 30, 2011 excludes stock-based compensation expense of $0.1 million and $0.4 million, respectively.

(e) Litigation-Related Charges

Our Adjusted EBITDA excludes certain litigation-related charges, which are incurred in connection with extraordinary litigation matters that are inherently unpredictable, highly variable from period to period, are not reasonably expected to recur in future periods or are not related to the day to day operational activities of our business.

No litigation related charges were adjusted from our GAAP-based net income for the three and six months ended June 30, 2012 to derive our Adjusted EBITDA metric. Our Adjusted EBITDA for the three and six months ended June 30, 2011 excludes litigation-related charges of nil and $0.2 million, respectively.

(f) Non-Recurring Production Charges

Our Adjusted EBITDA excludes amounts recorded for certain extraordinary and non-recurring production costs. These amounts are adjusted from our Adjusted EBITDA because they are unplanned, difficult to predict and related to one-time events not expected to recur from period to period.

Net income for the three and six months ended June 30, 2011 includes $9.8 million in additional cost of products sold expense related to the revaluation of inventory from $37.5 million to $60.1 million in connection with the Company's implementation of fresh start accounting on April 30, 2011. Given that this is a non-cash, non-recurring charge, we have added back this $9.8 million fresh start accounting related adjustment to our Adjusted EBITDA for the three and six months ended June 30, 2011.

(g) Foreign Exchange Gains and Losses

Our Adjusted EBITDA excludes amounts recorded for certain foreign exchange gains and losses. These amounts, which are added back to our GAAP-based net income (loss), primarily represent expenses related to differences arising from translating assets held by us in foreign territories and denominated in foreign currencies, into our reporting currency. These foreign currency assets fund our research and development activities in Canada, and are unique to our current operational structure. As they have no bearing on our day-to-day operations, operating decisions or our ability to fund or manage our operations or research and development programs, we exclude them from our non-GAAP Adjusted EBITDA.

Our Adjusted EBITDA for the three and six months ended June 30, 2012 excludes net foreign exchange gains of $0.2 million and net foreign exchange losses of $0.1 million, respectively.

Our Adjusted EBITDA for the three and six months ended June 30, 2011 excludes net foreign exchange gains of $0.1 million and net foreign exchange losses of $0.2 million, respectively.

(h) Impairment Charges and Unrealized Losses on Investments and Other Long-Lived Assets

Our Adjusted EBITDA excludes certain write-downs of investments or other long-lived assets, for which the carrying values are impaired and unlikely to recover. These amounts are added back to our GAAP-based net income (loss) because they are typically non-recurring, non-operating and non-cash write-downs or expense items, thus making it difficult to compare our operating performance in the period the impairment expense is incurred to our operating performance in other periods, or to the operating performance of similar companies in our industry. Management typically excludes these charges from our operating goals, forecasts, budgets and other non-GAAP financial measures.

Our Adjusted EBITDA for the three months ended June 30, 2012 excludes: a $0.7 million write-down of leasehold improvements related to our downsizing of our Vancouver facility, a $0.1 million net realized loss on the sale of a portion of our holdings in a publicly traded biotechnology company and $0.02 million of net unrealized gains on the remaining shares currently held, which have been trading below their carrying value and which management intends to sell in the near term.

Our Adjusted EBITDA for the six months ended June 30, 2012 excludes: a $0.7 million write-down of leasehold improvements related to our downsizing of our Vancouver facility, a $0.2 million write-down of certain manufacturing equipment related to the termination of one of our product development projects, a $0.3 million loss realized on the sale of a portion of our holdings in a publicly traded biotechnology company; and a $0.04 million unrealized loss on the remaining shares currently held, which have been trading below their carrying value and which management intends to sell in the near term.

Our Adjusted EBITDA for the three months ended June 30, 2011 excludes a $0.6 million non-cash impairment charge recorded in April 2011 related to a property based in Vancouver, Canada that was sold in May 2011. In addition to the above noted non-cash impairment charge, our Adjusted EBITDA for the six months ended June 30, 2011 excludes a $0.2 million write-down of leasehold improvements related to our downsizing of rentable space at one of our manufacturing facilities.

(i) Non-Recurring Gains and Other Income

Our Adjusted EBITDA excludes certain extraordinary and non-recurring gains. These amounts are adjusted from our GAAP-based metrics because they are unplanned, difficult to predict and related to one-time events not expected to recur from period to period.

Our Adjusted EBITDA for the three months ended June 30, 2012 excludes net gains of $0.6 million from the sale of certain lab equipment in connection with the shutdown of our research and development facilities at our Vancouver headquarters. In addition to this non-recurring gain, our Adjusted EBITDA for the six months ended June 30, 2012 also excludes a $0.2 million gain from the sale of certain manufacturing equipment.

Our Adjusted EBITDA for the three and six months ended June 30, 2011 excludes a $67.3 million gain related to the settlement and extinguishment of our $250 million Subordinated Notes, $16 million of related interest obligations and $4.1 million of certain other liabilities that were subject to compromise as part of the Recapitalization Transaction.

Material Limitations

While we believe our measure of Adjusted EBITDA is a useful financial metric for the reasons stated above, there may be certain inherent limitations in this non-GAAP metric, including but not limited to:

• Exclusion of amortization and depreciation expense from our Adjusted EBITDA does not take into account the need for future capital spending, whether this is to support growth or to replace assets which are subject to wear and tear.
  
  
• Exclusion of write-downs, amortization and depreciation from our Adjusted EBITDA does not take into consideration the potential tax impacts or obligations which can materialize into actual future cash flows.
  
  
• As we use our own approach for calculating our Adjusted EBITDA, other companies may not make the same adjustments or disclose their financial data in a manner that would allow comparison of their results to our adjusted results, thus decreasing comparability of our adjusted financial measures as comparative analytical tools.
  
  
• Non-GAAP based adjustments may not take into account the full economic cost of running our business. For example, financing costs are required to raise capital, which is used to fund operations. Adjusted financial measures do not necessarily reflect these considerations.

As noted above, our Adjusted EBITDA is not a substitute for our GAAP-derived financial measures and statements. Adjusted EBITDA is used by management to supplement our GAAP disclosures and help investors and lenders gain a better understanding of our operating performance. It also provides investors, lenders, and our Board of Directors with access to the same data used by management to assess our operating performance. Management compensates for the foregoing limitations by ensuring that our GAAP disclosures are transparent and sufficient to provide readers with the information required to reconcile financial results and form unbiased conclusions.

 

SOURCE: Angiotech Pharmaceuticals, Inc.

Investor Relations and Corporate Communications
Angiotech Pharmaceuticals, Inc.
[phone]
[email protected]